Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.
Actively Recruiting
Parkinsons disease PD is a neurological disorder that affects the brain and worsens over time, with symptoms such as tremors, stiffness, and slow movement. This research aims to assess how effective FoslevodopaFoscarbidopa is in treating adults with advanced Parkinsons Disease in Belgium under routine clinical practice. Approximately 120 adult participants prescribed this treatment will be studied across multiple sites. Participants will receive FoslevodopaFoscarbidopa through subcutaneous infusion as directed by their doctors according to local guidelines. This observational study does not involve additional interventions beyond routine care. Participants will continue their usual treatment while being followed for up to 18 months. During the study, participants will attend regular hospital or clinic visits as part of their standard care. Researchers will monitor changes in symptoms, focusing on OFF time periods when medication effects wear off measured by a specific Parkinsons rating scale over approximately six months. The study involves no extra procedures or burdens beyond routine practice and aims to collect data on the treatments impact over time.
Actively Recruiting
Researchers are studying obefazimod to evaluate its effectiveness and safety as a treatment for adults with moderately to severely active Crohns disease who have not responded well or cannot tolerate conventional or advanced therapies. This Phase 2b trial compares obefazimod with a placebo to see if it can help control symptoms and improve disease activity. The study also aims to assess the long-term safety and tolerability of obefazimod during an extension period. The study includes three treatment phases a 12-week induction phase, a 40-week maintenance phase, and a 48-week extension phase. Participants receive one of four daily treatments obefazimod at doses of 50mg, 25mg, or 12.5mg, or a placebo. All treatments are taken once daily, ideally in the morning with food. The extension phase focuses on monitoring safety and tolerability compared to placebo. Participants will attend regular study visits for assessments including the Crohns Disease Activity Index and endoscopic scores to measure disease activity and response. Safety is monitored through adverse event reports and laboratory tests, including blood work for hematology, coagulation, and biochemistry at various weeks up to the end of the study. The total study duration spans several phases, allowing close observation of treatment effects and safety over time.
Actively Recruiting
The trial investigates how to best prevent postoperative endoscopic recurrence in patients with Crohns disease who have undergone ileocolonic resection with anastomosis. Researchers are comparing an endoscopy-driven approach to starting biological therapy only when signs of recurrence appear, versus starting systematic prophylactic biological therapy shortly after surgery. This pragmatic randomized trial aims to assess whether the endoscopy-driven strategy leads to similar rates of disease recurrence and other outcomes at week 86, while also evaluating clinical recurrence, safety, costs, work productivity, and quality of life. Additionally, endoscopic images will be used to develop a new scoring system for postoperative recurrence. Participants are randomly assigned to one of two groups. The systematic prophylaxis group starts biological therapy adalimumab, infliximab, ustekinumab, vedolizumab, or risankizumab within 14 to 40 days post-surgery, with specific dosing schedules depending on the drug. The endoscopy-driven group does not receive therapy until week 30, when an endoscopic evaluation is done those with recurrence then start biological therapy following induction and maintenance dosing. Dose optimization is allowed after week 32 in both groups based on clinical practice and drug monitoring. Randomization is stratified by therapy type and risk factors for recurrence. During the study, participants undergo clinical assessments including endoscopies at week 30 and week 86, blood tests, and monitoring of symptoms and quality of life. Researchers track disease recurrence by endoscopic scores and clinical indices like the Harvey-Bradshaw Index. Safety events, treatment adaptations, healthcare costs, and surgery rates are recorded. Study participation lasts until week 86 after surgery, with ongoing data collection to evaluate treatment impact and outcomes in this Crohns disease population.
Actively Recruiting
Researchers are evaluating a structured, evidence-based rehabilitation pathway called the R pathway for patients undergoing lumbar surgery due to radicular pain. This multicenter cluster randomized controlled trial compares the R pathway against usual care to see if it can reduce the time it takes for patients to return to work after surgery. The study focuses on patients aged 18 to 65 scheduled for lumbar spinal surgery with radicular pain lasting at least six weeks. The R rehabilitation pathway involves coordinated care guided by a case manager, starting before surgery and continuing up to one year afterward. It includes prehabilitation, perioperative rehabilitation, and postoperative rehabilitation, aiming to reduce fear by minimizing unnecessary activity restrictions, eliminating bracing, and actively encouraging return to work. Hospitals are randomized to either implement the R pathway or continue with their usual variable rehabilitation care, which may include no rehabilitation or various types of therapy. Participants will be monitored from surgery through 15 months postoperatively. Researchers will assess the time to return to work as the primary outcome. Secondary outcomes include disability, percentage of patients returned to work, functional status, back and leg pain, health-related quality of life, work productivity, analgesic use, kinesiophobia, and pain catastrophizing at multiple time points. The study requires written consent and involves follow-up assessments to evaluate recovery and work reintegration.
Actively Recruiting
Researchers are evaluating the effectiveness of 2LPAPI4, an immune regulator, in clearing genital high-risk human papillomavirus HR-HPV infections in women aged 25 to 45. This condition is commonly studied in the cervix and vagina, and since 2025, screening in Belgium uses HPV testing as a primary method for cervical cancer prevention. The trial aims to compare 2LPAPI4 with a placebo to assess its impact on clearing HR-HPV infections over a 12-month period. Participants will be randomly assigned to receive either 2LPAPI4 or a placebo. The treatment involves taking one capsule daily on an empty stomach, 15 to 30 minutes before breakfast, following a sequence of numbered capsules for six continuous months. After the treatment phase, there is a six-month follow-up period to monitor the clearance of HR-HPV infections and cytology normalization. The study plans to include 284 women, divided equally between the two groups. During the study, participants will undergo routine screening visits for cervical cancer prevention, including cytology and HPV testing at baseline, six months, and twelve months. Researchers will track the clearance rates of HR-HPV, changes in cytology results, and safety through adverse event monitoring. The total study duration spans up to 72 months, with 60 months for participant inclusion and 12 months for follow-up to evaluate treatment success and safety outcomes.
Actively Recruiting
Crohns disease CD and ulcerative colitis UC are chronic inflammatory disorders affecting the gastrointestinal tract and colon, respectively. This research aims to assess the long-term effectiveness and safety of the drug upadacitinib in real-world clinical practice for adults with moderate to severe CD and UC. The study will observe participants prescribed upadacitinib according to local medical guidelines. Participants will receive upadacitinib as prescribed by their physicians based on routine clinical care and local label instructions. Approximately 280 adults across eight sites in Belgium will be enrolled. The treatment and monitoring will follow usual clinical practice without additional procedures imposed by the study. Participants will be followed for up to three years with regular visits at hospitals or clinics as part of their normal care. The research team will measure how many participants achieve clinical remission using specific scoring methods for UC and CD up to about 52 weeks. There is no expected extra burden beyond standard care during the study period.
Actively Recruiting
The trial investigates treatment options for adults with inflammatory bowel diseases IBD, including Crohns disease and ulcerative colitis, focusing on patients who were previously treated with an optimized dose of intravenous infliximab. The study aims to compare if switching to weekly subcutaneous infliximab leads to better clinical and biological remission outcomes than the standard bi-weekly subcutaneous administration. It also compares patients willing to switch to subcutaneous treatment with those continuing intravenous therapy. Participants who switch from intravenous infliximab will be randomly assigned to receive either 120 mg of subcutaneous infliximab weekly or every other week. Those not willing to switch will continue their existing intravenous dosing schedule. The study is conducted nationally with multiple centers, involving screening and follow-up visits over one year, with physical exams, clinical scoring, blood and stool analyses, and questionnaires about quality of life and treatment satisfaction. During the study, participants will have four visits with their gastroenterologist throughout one year, where clinical remission scores, lab tests, and medication use are assessed. Those on subcutaneous infliximab will keep a diary of at-home injections and complete satisfaction questionnaires. The primary measurement is the proportion of patients maintaining steroid-free clinical and biological remission without treatment changes at week 52. Researchers will also monitor treatment optimization, discontinuation, relapse timing, and patient experiences.